Heritage Is First To Settle DOJ Generic Drug Price Fixing Probe

Heritage agrees to pay $7.1m to resolve civil allegations and a $225,000 criminal penalty. DOJ defers prosecution of one felony charge.

Washington DC - Department of Justice Building
US Department of Justice, Washington DC

Heritage Pharmaceuticals Inc. is paying a relatively small sum to be free of the US Department of Justice's industry wide probe of generic price fixing. It remains to be seen if other generic manufacturers will enter similar settlements and how great their liability might be.

Heritage agreed to pay $7.1m to resolve allegations under the False Claims Act that it engaged in a price-fixing conspiracy....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

US Federal Circuit Says No To Teva And Viatris On Remanded Invega Sustenna Appeal

 
• By 

Just days after Viatris was frustrated in its attempts to challenge IP protecting Janssen’s Invega Trinza, the US Federal Circuit has rejected the firm’s and Teva’s bid to invalidate a patent shielding the one-month version of the brand, Invega Sustenna.

‘Prescription Drugs Are Not Golf Balls’ – Opinions Clash On Patents During FTC/DOJ Listening Session

 

Pro-innovator voices argued that the number of patents asserted in the pharma industry is not too dissimilar to other fields. But should drugs be compared to golf balls?

Zydus Trastuzumab Suit Dismissed In India For ‘Illusion Of Cause Of Action’

 
• By 

After nearly a decade of procedural delays, a Bombay High Court has finally tossed Zydus Cadila’s pre-emptive complaint against Roche over its Herceptin biosimilar, calling it an “illusion” of a real dispute.

Alchem Fined Over Buscopan API Cartel

 
• By 

After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.

More from Generics Bulletin

Bakers And Fishermen: How Biosimilars Manufacturers Are Bridging The Skills Gap

 
• By 

At Medicines for Europe’s annual conference in Brussels, executives from Polpharma Biologics and Gedeon Richter spoke about the challenges in finding biosimilars manufacturing staff with the right backgrounds – and how they are looking to other industries to bridge the skills gap.

US Federal Circuit Says No To Teva And Viatris On Remanded Invega Sustenna Appeal

 
• By 

Just days after Viatris was frustrated in its attempts to challenge IP protecting Janssen’s Invega Trinza, the US Federal Circuit has rejected the firm’s and Teva’s bid to invalidate a patent shielding the one-month version of the brand, Invega Sustenna.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, which houses flagship publications Generics Bulletin, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.